Avid Bioservices Inc (CDMO)

[entdoc]

md1225 & cjgaddy, the synopsis is a bit confusing. Perhaps U2 or others can clarify the apparent contradictions:
"METHODS: Patients with locally advanced or metastatic HCC deemed ineligible for curative therapy with NO PREVIOUS SYSTEMIC TREATMENT:
RESULTS: 38 patients were accrued, 7 still on treatment. Patient characteristics: median age: 60.5 years, male 74%, HCV: 79%, Black: 47%/Hispanic: 29%/White: 21%, PREVIOUS TREATMENT 37%..."

I suppose that means locally or surgically treated patients were a part of the trial?

"[Patients were treate]... until disease progression or intolerable toxicity. 38 patients were accrued
"RESULTS: 38 patients were accrued, 7 still on treatment."

So 7 of 38 are still being treated with no progression of disease. Very good.
However, Four month PFS is 76%. Great result.
But what does this mean? "...and there are no partial or complete responses."

Also, "Six patients had tissue analyzed pre- and post-treatment, 2 of 6 demonstrated increase tumor infiltration of CD4+, CD8+, and macrophages with a corresponding decrease in Tregs."

Not sure what a "Tregs" is. Surprised that only 2 of six had increased tumor infiltration of Cd4 etc. Wonder what that subgroup looks like.

Interesting stuff.

I agree with you MD1225, this could/should be a winner for Bavituximab in early liver carcinoma. AND, I have not been particularly upbeat about that possibility until reading this synopsis. Very impressive.

There must be some reserations out there in the world of liver treaters though. Possibly the 10% confidence level provided by the small cohort.

Reminds me of my favorite duble entendre:
"Life is only as good as the liver" !!